Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1037

1.

Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply.

Lu H, Graham DY.

Aliment Pharmacol Ther. 2019 Aug;50(3):332. doi: 10.1111/apt.15373. No abstract available.

2.

Rofecoxib and Clinically Significant Gastrointestinal Events: Response.

Graham DY, Jewell NP, Chan FKL.

Am J Med Sci. 2019 Jul 10. pii: S0002-9629(19)30204-6. doi: 10.1097/MAJ.0000000000000222. [Epub ahead of print] No abstract available.

PMID:
31301755
3.

Dietary quality and the colonic mucosa-associated gut microbiome in humans.

Liu Y, Ajami NJ, El-Serag HB, Hair C, Graham DY, White DL, Chen L, Wang Z, Plew S, Kramer J, Cole R, Hernaez R, Hou J, Husain N, Jarbrink-Sehgal ME, Kanwal F, Ketwaroo G, Natarajan Y, Shah R, Velez M, Mallepally N, Petrosino JF, Jiao L.

Am J Clin Nutr. 2019 Jul 10. pii: nqz139. doi: 10.1093/ajcn/nqz139. [Epub ahead of print]

PMID:
31291462
4.

Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging.

Rugge M, Sacchi D, Graham DY, Genta RM.

Gut. 2019 Jun 11. pii: gutjnl-2019-319107. doi: 10.1136/gutjnl-2019-319107. [Epub ahead of print] No abstract available.

PMID:
31186295
5.

High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.

Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, Lu H.

Helicobacter. 2019 Aug;24(4):e12596. doi: 10.1111/hel.12596. Epub 2019 May 20.

PMID:
31111580
6.

Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor.

Dore MP, Bibbò S, Pes GM, Francavilla R, Graham DY.

Can J Infect Dis Med Microbiol. 2019 Apr 1;2019:3409820. doi: 10.1155/2019/3409820. eCollection 2019.

7.

Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.

Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H.

Aliment Pharmacol Ther. 2019 Jun;49(11):1385-1394. doi: 10.1111/apt.15273. Epub 2019 Apr 24.

PMID:
31020673
8.

Current and Future Treatment of Helicobacter pylori Infections.

Matsumoto H, Shiotani A, Graham DY.

Adv Exp Med Biol. 2019 Apr 24. doi: 10.1007/5584_2019_367. [Epub ahead of print]

PMID:
31016626
9.

Changes of tight junction and interleukin-8 expression using a human gastroid monolayer model of Helicobacter pylori infection.

Uotani T, Murakami K, Uchida T, Tanaka S, Nagashima H, Zeng XL, Akada J, Estes MK, Graham DY, Yamaoka Y.

Helicobacter. 2019 Jun;24(3):e12583. doi: 10.1111/hel.12583. Epub 2019 Apr 5.

PMID:
30950121
10.

Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon.

Gurwara S, Ajami NJ, Jang A, Hessel FC, Chen L, Plew S, Wang Z, Graham DY, Hair C, White DL, Kramer J, Kourkoumpetis T, Hoffman K, Cole R, Hou J, Husain N, Jarbrink-Sehgal M, Hernaez R, Kanwal F, Ketwaroo G, Shah R, Velez M, Natarajan Y, El-Serag HB, Petrosino JF, Jiao L.

Nutrients. 2019 Mar 13;11(3). pii: E613. doi: 10.3390/nu11030613.

11.

Pantoprazole in Patients in the ICU.

Tan MC, Tansel A, Graham DY.

N Engl J Med. 2019 Mar 7;380(10):984. doi: 10.1056/NEJMc1900206. No abstract available.

PMID:
30855751
12.

The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal.

Wu JY, Lee YC, Graham DY.

Expert Rev Gastroenterol Hepatol. 2019 Jan;13(1):17-24. doi: 10.1080/17474124.2019.1542299. Epub 2018 Nov 13. Review.

PMID:
30791844
13.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1420. doi: 10.1016/j.cgh.2019.01.039. Epub 2019 Jan 30. No abstract available.

PMID:
30710706
14.

Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model.

Ihekweazu FD, Fofanova TY, Queliza K, Nagy-Szakal D, Stewart CJ, Engevik MA, Hulten KG, Tatevian N, Graham DY, Versalovic J, Petrosino JF, Kellermayer R.

Gut Microbes. 2019;10(4):504-520. doi: 10.1080/19490976.2018.1560753. Epub 2019 Jan 21.

PMID:
30663928
15.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):2005-2006. doi: 10.1016/j.cgh.2018.08.035. No abstract available.

PMID:
30454939
16.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):2004. doi: 10.1016/j.cgh.2018.08.031. No abstract available.

PMID:
30454938
17.

Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.

Graham DY, Lu H, Dore MP.

Helicobacter. 2019 Feb;24(1):e12554. doi: 10.1111/hel.12554. Epub 2018 Nov 15.

PMID:
30440097
18.

Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?

Leow AH, Azmi AN, Loke MF, Vadivelu J, Graham DY, Goh KL.

J Dig Dis. 2018 Nov;19(11):674-677. doi: 10.1111/1751-2980.12679. Epub 2018 Nov 8.

PMID:
30307122
19.

Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything?

Graham DY.

Dig Dis Sci. 2019 Jan;64(1):4-6. doi: 10.1007/s10620-018-5288-9. No abstract available.

PMID:
30238199
20.

Guilt by association: intestinal metaplasia does not progress to gastric cancer.

Graham DY, Zou WY.

Curr Opin Gastroenterol. 2018 Nov;34(6):458-464. doi: 10.1097/MOG.0000000000000472.

PMID:
30138135
21.

Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Graham DY, Dore MP, Lu H.

Expert Rev Anti Infect Ther. 2018 Sep;16(9):679-687. doi: 10.1080/14787210.2018.1511427. Epub 2018 Aug 23. Review.

PMID:
30102559
22.

Enzyme therapy for functional bowel disease-like post-prandial distress.

Graham DY, Ketwaroo GA, Money ME, Opekun AR.

J Dig Dis. 2018 Nov;19(11):650-656. doi: 10.1111/1751-2980.12655. Epub 2018 Sep 21. Review.

PMID:
30101562
23.

Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: A mini review.

Graham DY, Miftahussurur M.

J Adv Res. 2018 Jan 31;13:51-57. doi: 10.1016/j.jare.2018.01.006. eCollection 2018 Sep. Review.

24.

Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.

Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-Thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. Epub 2018 Jul 2.

PMID:
30042064
25.

Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.

Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E.

Gastroenterology. 2018 Nov;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007. Epub 2018 Jul 7. Review.

PMID:
29990487
26.

Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply.

Yeomans ND, Graham DY.

Aliment Pharmacol Ther. 2018 Jun;47(11):1546-1547. doi: 10.1111/apt.14656. No abstract available.

PMID:
29878426
27.

Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.

Reed GW, Abdallah MS, Shao M, Wolski K, Wisniewski L, Yeomans N, Lüscher TF, Borer JS, Graham DY, Husni ME, Solomon DH, Libby P, Menon V, Lincoff AM, Nissen SE.

J Am Coll Cardiol. 2018 Apr 24;71(16):1741-1751. doi: 10.1016/j.jacc.2018.02.036.

28.

Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis.

Wang Z, Graham DY, Khan A, Balakrishnan M, Abrams HR, El-Serag HB, Thrift AP.

Int J Epidemiol. 2018 Apr 16. doi: 10.1093/ije/dyy055. [Epub ahead of print]

29.

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.

Yeomans ND, Graham DY, Husni ME, Solomon DH, Stevens T, Vargo J, Wang Q, Wisniewski LM, Wolski KE, Borer JS, Libby P, Lincoff AM, Lüscher TF, Bao W, Walker C, Nissen SE; PRECISION investigators.

Aliment Pharmacol Ther. 2018 Jun;47(11):1453-1463. doi: 10.1111/apt.14610. Epub 2018 Apr 17.

PMID:
29667211
30.

Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial.

Hsu PI, Tsay FW, Graham DY, Tsai TJ, Tsai KW, Kao JY, Peng NJ, Kuo CH, Kao SS, Wang HM, Lin TF, Wu DC; Taiwan Acid-related Disease (TARD) Study Group.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1427-1433. doi: 10.1016/j.cgh.2018.03.031. Epub 2018 Mar 31.

PMID:
29609070
31.

Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer.

Tan MC, Graham DY.

BMJ Evid Based Med. 2018 Jun;23(3):111-112. doi: 10.1136/bmjebm-2018-110935. Epub 2018 Mar 29. Review. No abstract available.

PMID:
29599181
32.

Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe S, Elfant A, Haas T, Hapke RJ, Graham DY.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002.e6. doi: 10.1016/j.cgh.2018.03.013. Epub 2018 Mar 17. Erratum in: Clin Gastroenterol Hepatol. 2019 Mar;17(4):801.

PMID:
29559361
33.

Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals.

Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, Chen L, Wong ICK, Graham DY.

Gastroenterology. 2018 Jul;155(1):67-75. doi: 10.1053/j.gastro.2018.03.028. Epub 2018 Mar 14.

PMID:
29550592
34.

An Investigation into the Recent Increase in Gastric Cancer in the USA.

Balakrishnan M, George R, Sharma A, Graham DY, Malaty HM.

Dig Dis Sci. 2018 Jun;63(6):1613-1619. doi: 10.1007/s10620-018-5012-9. Epub 2018 Mar 15.

PMID:
29546646
35.

Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial.

Yeomans ND, Graham DY, Wang Q, Wolski K, Borer J, Husni EM, Libby P, Lincoff MA, Lüscher T, Wisniewski LM, Bao W, Walker C, Nissen SE.

Am J Gastroenterol. 2018 Jul;113(7):1053-1054. doi: 10.1038/s41395-018-0051-6. No abstract available.

PMID:
29535414
36.

Brief report: Lactobacillus bulgaricus GLB44 (Proviotic ) plus esomeprazole for Helicobacter pylori eradication: A pilot study.

Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY.

Helicobacter. 2018 Apr;23(2):e12476. doi: 10.1111/hel.12476. Epub 2018 Mar 4.

PMID:
29504209
37.

Editorial: Helicobacter pylori and gastric cancer in Alaskan Natives: Time to stop studying H. pylori and to eradicate it.

Lee YC, Asaka M, Graham DY.

Helicobacter. 2018 Jun;23(3):e12478. doi: 10.1111/hel.12478. Epub 2018 Mar 2. No abstract available.

PMID:
29498154
38.

Update on the Use of Vonoprazan: A Competitive Acid Blocker.

Graham DY, Dore MP.

Gastroenterology. 2018 Feb;154(3):462-466. doi: 10.1053/j.gastro.2018.01.018. Epub 2018 Jan 11. No abstract available.

PMID:
29337157
39.

Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients.

Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, Pretis G, Graham DY, Genta RM.

Gut. 2019 Jan;68(1):11-17. doi: 10.1136/gutjnl-2017-314600. Epub 2018 Jan 6.

PMID:
29306868
40.

Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection.

Bhakta D, Graham DY, Chan J, El-Serag HB.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1531-1532. doi: 10.1016/j.cgh.2017.12.040. Epub 2018 Jan 3. No abstract available.

PMID:
29306045
41.

Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.

Solomon DH, Husni ME, Wolski KE, Wisniewski LM, Borer JS, Graham DY, Libby P, Lincoff AM, Lüscher TF, Menon V, Yeomans ND, Wang Q, Bao W, Berger MF, Nissen SE; PRECISION Trial Investigators.

Arthritis Rheumatol. 2018 Apr;70(4):537-546. doi: 10.1002/art.40400.

42.

Editorial: recurrence of Helicobacter pylori infection-still the same after all these years… Authors' reply.

Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH.

Aliment Pharmacol Ther. 2018 Jan;47(1):132-133. doi: 10.1111/apt.14386. No abstract available.

43.

Mechanical colon cleansing for screening colonoscopy: A randomized controlled trial.

Ayub K, Ketwaroo G, Abudayyeh S, Ibrahim A, Cole RA, Brumfield-Brown R, Qureshi WA, Rabeneck L, Graham DY.

J Dig Dis. 2017 Dec;18(12):691-697. doi: 10.1111/1751-2980.12562.

PMID:
29160622
44.

Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis.

Graham DY.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1117-1118. doi: 10.1111/apt.14339. No abstract available.

45.

Genome and Methylome Variation in Helicobacter pylori With a cag Pathogenicity Island During Early Stages of Human Infection.

Nell S, Estibariz I, Krebes J, Bunk B, Graham DY, Overmann J, Song Y, Spröer C, Yang I, Wex T, Korlach J, Malfertheiner P, Suerbaum S.

Gastroenterology. 2018 Feb;154(3):612-623.e7. doi: 10.1053/j.gastro.2017.10.014. Epub 2017 Oct 21.

PMID:
29066327
46.

The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017.

Kuenstner JT, Naser S, Chamberlin W, Borody T, Graham DY, McNees A, Hermon-Taylor J, Hermon-Taylor A, Dow CT, Thayer W, Biesecker J, Collins MT, Sechi LA, Singh SV, Zhang P, Shafran I, Weg S, Telega G, Rothstein R, Oken H, Schimpff S, Bach H, Bull T, Grant I, Ellingson J, Dahmen H, Lipton J, Gupta S, Chaubey K, Singh M, Agarwal P, Kumar A, Misri J, Sohal J, Dhama K, Hemati Z, Davis W, Hier M, Aitken J, Pierce E, Parrish N, Goldberg N, Kali M, Bendre S, Agrawal G, Baldassano R, Linn P, Sweeney RW, Fecteau M, Hofstaedter C, Potula R, Timofeeva O, Geier S, John K, Zayanni N, Malaty HM, Kahlenborn C, Kravitz A, Bulfon A, Daskalopoulos G, Mitchell H, Neilan B, Timms V, Cossu D, Mameli G, Angermeier P, Jelic T, Goethe R, Juste RA, Kuenstner L.

Front Public Health. 2017 Sep 27;5:208. doi: 10.3389/fpubh.2017.00208. eCollection 2017.

47.

Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.

Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Lüscher TF, Solomon DH, Husni ME, Graham DY, Davey DA, Wisniewski LM, Menon V, Fayyad R, Beckerman B, Iorga D, Lincoff AM, Nissen SE.

Eur Heart J. 2017 Nov 21;38(44):3282-3292. doi: 10.1093/eurheartj/ehx508.

PMID:
29020251
48.

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

Graham DY, Tansel A.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7. doi: 10.1016/j.cgh.2017.09.033. Epub 2017 Sep 28.

PMID:
28964908
49.

Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?

Graham DY, Lu H, Shiotani A.

Saudi J Gastroenterol. 2017 Sep-Oct;23(5):265-267. doi: 10.4103/sjg.SJG_292_17. No abstract available.

50.

Illusions regarding Helicobacter pylori clinical trials and treatment guidelines.

Graham DY.

Gut. 2017 Dec;66(12):2043-2046. doi: 10.1136/gutjnl-2017-314744. Epub 2017 Sep 21. No abstract available.

PMID:
28935677

Supplemental Content

Loading ...
Support Center